drugset / Trial / NCT00004915
Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer
Treatment
Summary
RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using raloxifene may fight endometrial cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of raloxifene in treating patients who have persistent or recurrent endometrial cancer.
Timeline
- Start
- 1998-11
- Primary completion
- 2000-02
- Completion
- 2000-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Raloxifene | Other / unclassified | — | Oral |